H.C. Wainwright raised the firm’s price target on Okyo Pharma to $7 from $6 and keeps a Buy rating on the shares. OK-101 achieved statistical significance for multiple signs and symptoms of dry eye disease, the analyst tells investors in a research note. The firm believes OK-101’s “rapid onset of action, durable improvement and placebo-like tolerability profile” compare favorably to the established therapies on the market. This could make OK-101 a preferred choice by physicians and patients if it obtains regulatory approval, says the firm, which increased the probability of approval to 35% from 30%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKYO:
- OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
- OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
- OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
- Okyo Pharma to release new data from Phase 2 dry eye disease trial
- Okyo Pharma price target raised to $6 from $5 at H.C. Wainwright
